Home/Pipeline/PanGIA Prostate Assay

PanGIA Prostate Assay

Prostate Cancer

Pre-clinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Pre-clinical

Status

Active

Company

PanGIA Biotech

About PanGIA Biotech

PanGIA Biotech is pioneering an AI-driven, multi-fluid diagnostic platform centered on a non-invasive 'True Liquid Biopsy' using urine. The company's PanGIA Analysis System (PAS) applies machine learning to colorimetric biomolecular profiles to detect early-stage cancers with the goal of improving accuracy, accessibility, and patient comfort over traditional methods like blood tests or tissue biopsies. While its lead PanGIA Prostate assay is in use globally for diagnostic research, the company is navigating the path toward FDA approval and commercial scale-up to address the significant global need for better early cancer detection.

View full company profile

Therapeutic Areas

Oncology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active